Drug Discovery World

OCTOBER 11, 2023

Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021. GA is an irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD).

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Pharmaceuticals Therapies Production 49

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. Pfizer and BioNTech completed the rolling submission of the BLA in May 2021. About BioNTech.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

The Pharma Data

MAY 14, 2021

Product Name: Home – Beat Kidney Disease – 2020 – Beat Kidney Disease. Home – Beat Kidney Disease – 2020 – Beat Kidney Disease is backed with a 60 Day No Questions Asked Money Back Guarantee. Description: Copyright © 2009 – 2021 BeatKidneyDisease.com All Rights Reserved.

Disease 52

Disease Production Licensing Licensing 52

Drug Discovery World

SEPTEMBER 21, 2022

LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease that is suggested to cause irreversible nephron loss. The combination treatment for this indication was approved by the US Food and Drug Administration in 2021 and gained a positive opinion from the CHMP earlier this year.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — ImaginAb Inc. , a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 11, 2021

11, 2021 23:59 UTC. a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

Drug Discovery World

JANUARY 17, 2023

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData. . Leqembi is the second anti-Aβ mAb approved by the FDA for the treatment of AD, following the FDA’s approval of Biogen’s Aduhelm (aducanumab) in 2021. .

FDA 130

FDA Clinical Trials Licensing Licensing 130

The Pharma Data

DECEMBER 13, 2020

Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for omidubicel with the U.S. With this clarity, we look forward to proceeding towards a full BLA submission in the second half of 2021. About Omidubicel.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

JULY 29, 2021

today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company. “We Reports Second Quarter Revenues of $11.7 and Non-GAAP EPS of $1.93 board chair and chief executive officer, Bristol Myers Squibb. “We

Production 52

Production International Licensing Licensing 52

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. AUTHORIZED USE IN THE U.S.:

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc.,

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. As a result, we expect a 50-60% year-over-year Parsabiv sales decline in 2021.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. CET on January 27, 2021. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Licensing Licensing 40

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. However, these trials won’t be complete until 2026 at the earliest.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

The Pharma Data

DECEMBER 16, 2020

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., The agreement leverages Otsuka’s well-recognized expertise in rare kidney diseases to underscore Aurinia’s commitment to expanding global access to voclosporin for the treatment of LN.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

MARCH 22, 2021

Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington’s disease (HD). In December 2017, Roche licensed the investigational molecule from Ionis Pharmaceuticals. About Huntington’s disease.

Disease 52

Disease Clinical Trials Pharmacokinetics Licensing 52

New Drug Approvals

SEPTEMBER 6, 2024

2 , 3 Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. 2] Lazertinib was approved for medical use in South Korea in January 2021, [4] [5] and in the United States in August 2024. [2] 20 August 2024. 20 August 2024.

FDA Approval 62

FDA Approval FDA International Clinical Trials 62

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

APRIL 30, 2021

April 30, 2021 /PRNewswire/ — AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. “We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said Richard A. .

FDA 40

FDA Production Treatment International 40

The Pharma Data

JANUARY 25, 2021

25, 2021 (GLOBE NEWSWIRE) — Ambulero, Inc. , a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. MIAMI, Jan.

Therapies 52

Therapies Disease Licensing Licensing 52

Drug Discovery World

JULY 2, 2024

OECD data places Switzerland second in the world for biotechnology R&D intensity 1 , and in 2021, the country had the seventh largest share of the global biotech market 2. References [link] [link]. link] The post Drug discovery hotspots: What is the secret to Switzerland’s success?

Science 147

Science Drugs Clinical Trials Licensing 147

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

SEPTEMBER 26, 2022

It’s also why pharmaceutical companies will look to acquire smaller biotechs and drug discovery companies, because a lot of the legwork into finding a suitable molecule for a disease has already been done. . This level of growth is unsurprising for an industry which will always look to the latest opportunities to drive science. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

The Pharma Data

JANUARY 10, 2021

11, 2021 06:35 UTC. Morgan Healthcare’ annual conference, taking place from 11 to 14 January 2021, in virtual format. WAINWRIGHT BioConnect 2021 conference. Its products are intended to be licensed to players in the health sector. At the same time, VALBIOTIS is also participating in the H.C.

International 40

International Pharmaceutical Companies Licensing Licensing 40

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Licensing 52

Licensing Licensing Therapies Protein Expression 52

The Pharma Data

OCTOBER 27, 2020

Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease (RPD) designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). Passage Bio expects to initiate a Phase 1/2 trial for PBKR03 in the first half of 2021. About Krabbe Disease.

Disease 40

Disease FDA Treatment Clinical Trials 40

The Pharma Data

JANUARY 12, 2021

12, 2021 — Ebola vaccines are being stockpiled by the World Health Organization and other groups to combat future outbreaks of the deadly disease. Before it was licensed, the Merck Ebola vaccine was used under a “compassionate use” protocol to control outbreaks in Guinea and Congo, the AP reported.

Vaccine 52

Vaccine Licensing Licensing Doctors 52

The Pharma Data

JANUARY 18, 2021

19, 2021 /PRNewswire/ — Yesse Technologies, Inc. , The funds will be used to advance its nose-on-chip platform to detect the characteristic smell linked to Parkinson’s disease (PD). The funds will be used to advance its nose-on-chip platform to detect the characteristic smell linked to Parkinson’s disease (PD).

Disease 40

Disease Molecular Biology Licensing Licensing 40

The Pharma Data

NOVEMBER 6, 2020

The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of Alzheimer’s disease.

Disease 40

Disease FDA Clinical Trials Licensing 40

Drug Discovery World

FEBRUARY 9, 2023

The MHRA has been a Project Orbis partner since 1 January 2021. The MHRA has been a Project Orbis partner since 1 January 2021. This means durvalumab is eligible for inclusion in the Innovative Licensing and Access Pathway (ILAP). Whilst this disease is uncommon, the incidence is rising. 4 Updated median OS was 12.9

Treatment 130

Treatment Clinical Research International FDA 130

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. 19, 2021 /PRNewswire/ — Vera Therapeutics, Inc. , The proceeds will also be used to scale the company’s manufacturing capabilities and expand Vera’s therapeutic pipeline in immunologic and inflammatory disease.

Disease 52

Disease Science Clinical Development Treatment 52

The Pharma Data

OCTOBER 29, 2020

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease. If approved, aducanumab would become the first therapy to reduce the clinical decline in patients with Alzheimer’s disease. CAMBRIDGE, Mass.

Marketing 40

Marketing Disease Clinical Trials Treatment 40

Drug Target Review

JULY 19, 2023

Most vaccines cannot be self-administered, so distribution requires access to trained healthcare services – a big problem in developing countries, which is where infectious disease burdens are highest. A leading company in this field, Seattle’s Lumen Bioscience, is best known for its orally delivered antibodies targeting diseases such as C.

Vaccine 96

Vaccine Engineering Disease Virus 96